Search - tctmd.com

Displaying 21 - 40 of 56

Sort: Relevancy | Date

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

Presentation ESC 2019

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Presenter: Deepak Bhatt

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

Presentation ESC 2018

ASCEND Randomized placebo-controlled trial of aspirin

Presenter: Jane Armitage

August 27, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

Todd Neale

August 26, 2018

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

Advertisement

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Top News in Prevention: 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

TCTMD’s Top 10 Most Popular Stories for August 2018

ASCEND Randomized placebo-controlled trial of aspirin

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content